March 22, 2024 5:29pm

So far this month; 10 negative and 6 positive closes while most of my covered (35) companies are down after reporting earnings with 28 reported, 7 remain to release

Pre-open Indications: 4 Hits and 2 Miss  

Subscription is coming; a “buck” a day will keep your portfolio in play - be a subscriber to continue reading!  A 360-degree review of the who, why, when and what happened in the sector as the market and economics surround your portfolio defense.

Never leave an investor uninformed! A trusted source of factual reporting!

The week in review

The present and future value of RegMed Investors (RMi) NEWS sheds light on the stem, cell and gene therapy sector’s risks to share pricing and the sector’s upside acrobatics and potential downslides.

I write this blog/newsletter to inform investors with facts and supporting numbers focused on what they need to hear that others will not say or write about – facts in evidence! 

 

Friday: The Dow closed DOWN -305.47 points or -0.77%, the S&P closed DOWN -7.35 points -0.14% while the Nasdaq closed UP +26.98 points or +0.16%

 

Henry’omics:

We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy companies …

Indexes lipped on Friday with the Dow and S&P down and the Nasdaq barely up, but headed toward its best week of the year after back-to-back record-setting sessions.

For the week, the S&P 500 was up +2.3%, the Dow up +2.1% and the Nasdaq jumped +2.8%.

 

Friday’s RegMed Investors’ (RMi) opening bell: “Buy or fly, trade or fade?  Risk-on or Risk-off (RORO) can also sway changes in investment activity in response to economic patterns.” …  https://www.regmedinvestors.com/articles/13385

 

Pre-open Indications: 4 Hits < CRISPR Therapeutics (CRSP -$2.89), Vericel (VCEL +$0.21), Blueprint Medicine (BPMC -$3.01), Adverum Biotechnologies (ADVM +$0.31)> and 2 Miss < Alnylam Pharmaceuticals (ALNY -$0.11), Graphite Bio (GPPH -$0.09)>

 

Advance/Decline (A/D) Line:

  • Friday’s advance/decline line at the open was negative with 4 incliner, 30 decliners and 1 flat; ending with a negative close of 8 incliners, 27 decliners and 0 flat
  • Thursday’s advance/decline line at the open was negative with 16 incliner, 18 decliners and 1 flat; ending with a negative close of 14 incliners, 20 decliners and 1 flat
  • Wednesday’s advance/decline line at the open was negative with 3 incliner, 33 decliners and 2 flats; ending with a positive close of 26 incliners, 7 decliners and 2 flats
  • Tuesday’s advance/decline line at the open was positive with 18 incliner, 15 decliners and 2 flats; ending with a positive close of 23 incliners, 12 decliners and 0 flat
  • Monday’s advance/decline line at the open was negative with 4 incliner, 30 decliners and 1 flat; ending with a negative close of 8 incliners, 25 decliners and 2 flats

 

Ebb and flow of MY covered sector cell and gene therapy session daily “endings”:

Q1/24: March, 6 positive and 10 negative closes

  • February, 1 holiday, 9 negative and 11 positive closes
  • January: 2 holiday, 12 negative and 8 positive closes

 

Key Metrics:

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Friday, the IBB was down -0.71% and the XBI was down -1.75%
  • Thursday, the IBB was up +0.64% and the XBI was up +0.03%
  • Wednesday, the IBB was up +0.26% and the XBI was up +1.40%
  • Tuesday, the IBB was up +0.65% and the XBI was up +0.79%
  • Monday, the IBB was down -0.49% and the XBI was down -1.88%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Friday was up +0.04 point or+0.31% at 12.96.
  • Thursday was down -0.03 point or -0.23% at 13.02
  • Wednesday was down -0.77 point or -5.57% at 13.05
  • Tuesday was down -0.51% points or -3.56% at 13.82
  • Monday was up +0.02 point or +0.07% at 14.42

 

Friday’s Closing Down (10 of 27):

  • Blueprint Medicine (BPMC -$3.01 after Thursday’s +$1.79, Wednesday’s +$0.29, Tuesday’s +$1.15 and Monday’s -$3.88)
  • CRISPR Therapeutics (CRSP -$2.89 after Thursday’s +$1.56, Wednesday’s +$0.98, Tuesday’s +$0.49 and Monday’s -$1.48),
  • Beam Therapeutics (BEAM -$1.32),
  • Fate Therapeutics (FATE -$0.82),
  • Ultragenyx Pharmaceuticals (RARE -$0.80),
  • Sage Therapeutics (SAGE -$0.75 after Thursday’s +$0.29, Wednesday’s +$0.40, Tuesday’s -$0.09 and Monday’s -$0.60),
  • Intellia therapeutics (NTLA -$0.74 after Thursday’s -$0.13),
  • Regenxbio (RGNX -$0.72),
  • Prime Medicine (PRME -$0.41),
  • Voyager Therapeutics (VYGR -$0.39),

Friday’s Closing Up (8 of 8):

  • Adverum Biotechnologies (ADVM +$1.31 after Thursday’s -$0.45, Wednesday’s -$0.13, Tuesday’s -$0.12 and Monday’s +$0.07),
  • Solid Biosciences (SLDB +$1.13 after Thursday’s -$0.65, Wednesday’s -$1.48, Tuesday’s +$1.39 and Monday’s +$0.28),
  • BioLife Solutions (BLFS +$0.36 after Thursday’s +$0.35, Wednesday’s +$0.27 and Tuesday’s +$0.64),
  • Vericel (VCEL +$0.21 after Thursday’s +$0.94),
  • uniQure NV (QURE +$0.09),
  • Brainstorm Cell Therapeutics (BCLI +$0.09),
  • Homology Medicine (FIXX +$0.0428),
  • Cellectis SA (CLLS +$0.02),

 

Q1/24 – March

  • Friday closed negative with 8 incliners, 27 decliners and 0 flats
  • Thursday closed negative with 14 incliners, 20 decliners and 1 flat
  • Wednesday closed positive with 26 incliners, 7 decliners and 2 flats
  • Tuesday closed positive with 23 incliners, 12 decliners and 0 flat
  • (3/18) Monday closed negative with 8 incliners, 25 decliners and 2 flats

 

The BOTTOM LINE: it’s been a mixed week of ups and down, 3 negative and 2 positive closes.

  • It hopefully will be a quiet period next week, but there are still sector earnings and economic events to look out for.
  • Earlier in the week, the Fed left rates unchanged but signaled it was still on track for 3 rate cuts this year.

Earnings, net losses, and per-share losses, runways and guidance have begun Q4 and FY23 which WILL be crucial to continue downside force in the sector as history has taught us i.e., investors.

  • I have seen 4 net income for the Q4 and FY23 - MiMedx (MDXG) and Voyager Therapeutics (VYGR) followed by Q4 CRISPR Therapeutics (CRSP) and Beam Therapeutics (BEAM) <but each had a FY23 loss>
  • 28 have reported … RegMed Investors (RMi) - Q4/23 & FY23 Cell and Gene Therapy Earnings Scorecard Results
  • https://www.regmedinvestors.com/articles/11628

Still not finished with Q4 and FY23 earnings releases, remaining:

  • BLCM, OTCQB: HRGN, BLUE, BCLI, CLLS, GRPH, FIXX, IONS,

 

“I ALSO reiterate, “Don't chase the cell and gene therapy sector, especially with the Nasdaq extended.” Short and non-sweet: SELL into STRENGTH – accumulate some “powder” i.e., cash!

 

The top three (3) performing in the session:

  • Friday: Solid BioSciences (SLDB), Adverum Biotechnologies (ADVM) and BioLife Solutions (BLFS)
  • Thursday: Blueprint Medicine (BPMC), CRISPR Therapeutics (CRSP) and Vericel (VCEL)
  • Wednesday: CRISPR Therapeutics (CRSP), Ionis Pharmaceuticals (IONS) and Fate Therapeutics (FATE)
  • Tuesday: Blueprint Medicine (BPMC), Solid BioSciences (SLDB) and Vericel (VCEL)
  • Monday:  Solid BioSciences (SLDB), Regenxbio (RGNX) and Sangamo Therapeutics (SGMO)

The worst three (3) in the session:  

  • Friday: Blueprint Medicine (BPMC), CRISPR Therapeutics (CRSP) and Beam Therapeutics (BEAM)
  • Thursday: Alnylam Pharmaceuticals (ALNY), Voyager therapeutics (VYGR) and Solid BioSciences (SLDB),
  • Wednesday: Solid BioSciences (SLDB), Harvard Apparatus RT (OTCQB: HGGN) and Alnylam Pharmaceuticals (ALNY)
  • Tuesday: Verve Therapeutics (VERV), Graphite Bio (GRPH) and Adverum Biotechnologies (ADVM) 
  • Monday: Blueprint Medicine (BPMC), Alnylam Pharmaceuticals (ALNY) and CRISPR Therapeutics (CRSP) 

 

BEWARE… How MANY TIMES AM I RIGHT … MORE than MOST!!

The Harvard Apparatus RT (OTC QB HRGN) formerly Biostage (BSTG) Chronicles: shows how the “pimp/pump and promote” share pricing works with WHAT news for so long …my treatise is VALIDATED!

  • Friday closed down -$0.01 with 253 shares traded
  • Thursday closed up +$0.82 with 8,284 shares traded <3-mo aver = 3,721 shares>
  • Wednesday closed down -$0.97 with 8,835 shares traded
  • Tuesday closed up +$0.05 with 7000 shares traded
  • (3/18) Monday closed flat $0.00 with 624 shares traded

Did you notice how it barely trades unless volume is being “pumped.”  This question needs to be answered as HRGN is desperate to finance by any means as past Chinese private placement investors must be feeling … WHAT … TAKEN to the cleaners?

Question, Is it a Ponzi Scheme?

 

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities.

I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.